Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-9645 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-755 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-224 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
filingDate |
2015-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2017-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-WO2016047652-A1 |
titleOfInvention |
Method for measuring the reactivity of FVIII |
abstract |
An attempt was made to create a substance that neutralizes the activity of a bispecific antibody having an FVIII function-substituting activity, and to measure the reactivity of FVIII that is accurate even in the presence of this bispecific antibody. . As a result, we found that APTT-based one-stage clotting assay can accurately evaluate FVIII activity in the plasma of patients with hemophilia A, and APTT-based Bethesda assay showed that FVIII inhibitor hemophilia It was also found that the FVIII inhibitor titer in the plasma of disease A patients can be accurately evaluated. |
priorityDate |
2014-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |